Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

4.43
-0.0500-1.12%
Post-market: 4.430.00000.00%17:45 EDT
Volume:44.98K
Turnover:202.20K
Market Cap:246.28M
PE:-2.42
High:4.73
Open:4.57
Low:4.39
Close:4.48
Loading ...

Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy

TIPRANKS
·
08 Mar

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances

TIPRANKS
·
07 Mar

Foghorn Therapeutics Reports Progress and Financial Stability

TIPRANKS
·
07 Mar

Foghorn Therapeutics Inc. reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
07 Mar

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
07 Mar

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

GlobeNewswire
·
07 Mar

Foghorn Therapeutics Inc. expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
03 Mar

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses

Simply Wall St.
·
28 Feb

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Zacks
·
27 Feb

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
11 Feb

Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks

TipRanks
·
09 Feb

Techne (TECH) Tops Q2 Earnings and Revenue Estimates

Zacks
·
05 Feb

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Zacks
·
03 Feb

B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target

MT Newswires Live
·
30 Jan

Foghorn Therapeutics Initiated at Buy by B. Riley Securities

Dow Jones
·
30 Jan